Double-blind, placebo-controlled, randomised phase II trial of IH636 grape seed proanthocyanidin extract (GSPE) in patients with radiation-induced breast induration

Department of Radiotherapy, Royal Marsden Hospital, Sutton, Surrey, UK.
Radiotherapy and Oncology (Impact Factor: 4.36). 04/2006; 79(1):45-51. DOI: 10.1016/j.radonc.2006.02.008
Source: PubMed

ABSTRACT Tissue hardness (induration), pain and tenderness are common late adverse effects of curative radiotherapy for early breast cancer. The purpose of this study was to test the efficacy of IH636 grape seed proanthocyanidin extract (GSPE) in patients with tissue induration after high-dose radiotherapy for early breast cancer in a double-blind placebo-controlled randomised phase II trial.
Sixty-six eligible research volunteers with moderate or marked breast induration at a mean 10.8 years since radiotherapy for early breast cancer were randomised to active drug (n = 44) or placebo (n = 22). All patients were given grape seed proanthocyanidin extract (GSPE) 100 mg three times a day orally, or corresponding placebo capsules, for 6 months. The primary endpoint was percentage change in surface area (cm(2)) of palpable breast induration measured at the skin surface 12 months after randomisation. Secondary endpoints included change in photographic breast appearance and patient self-assessment of breast hardness, pain and tenderness.
At 12 months post-randomisation, > or =50% reduction in surface area (cm(2)) of breast induration was recorded in 13/44 (29.5%) GSPE and 6/22 (27%) placebo group patients (NS). At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of external assessments of tissue hardness, breast appearance or patient self-assessments of breast hardness, pain or tenderness.
The study failed to show efficacy of orally-administered GSPE in patients with breast induration following radiotherapy for breast cancer.

Download full-text


Available from: Emma Hall, Sep 28, 2015
1 Follower
48 Reads
  • Source
    • "Increased dietary intake, maintenance of weight, decreased fatigue [163] [164] [165] [166] [167] [168] [169] [170] Selenium selenite in breast cancer and head and neck cancer patients Decreased lymphedema [171–173, 180–182] Ginkgo in breast cancer patients Decreased lymphedema [174] Variety of high flavinoid extracts Decreased lymphedema [175] [176] [177] [178] [179] Carnitine in cancer patients following chemotherapy; benefit most pronounced in patients with carnitine deficiency Decreases fatigue [184] [185] [186] [187] Black cohosh extracts in breast cancer patients with menopausal symptoms Decreases vasomotor symptoms in some trials [189] [191] Green or black tea in leukoplakia Improved abnormality [194] [195] Green tea extract in high-grade intraepithelial neoplasia of the prostate without conventional therapy Decreased progression to frank prostate cancer [196] Pomegranate juice in prostate cancer patients with rising PSA after radiation or surgery Increased PSA-doubling time [197] Soy in complex formula in prostate cancer patients with rising PSA after radiation or surgery Increased PSA-doubling time [198] Lycopene in hormone refractory prostate cancer; in hormone responsive patients following orchiectomy Limited clinical response in some patients; Improved clinical response [199] [200] [201] 605 DIETARY SUPPLEMENTS: HELP OR HARM full disclosure of use. Nonjudgmental questioning and demonstration of greater knowledge of the research concerning dietary supplements by physicians should aid in this endeavor. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Conventional wisdom generally recommends complete avoidance of all dietary supplements, especially during chemotherapy and radiation. This interdiction persists, in spite of high rates of dietary supplement use by patients throughout all phases of cancer care, and can result in patients' perceptions of physicians as negative, thus leading to widespread nondisclosure of use. A review of the clinical literature shows that some evidence for harm does exist; however, data also exist that show benefit from using certain well-qualified supplements. Physicians should increase their knowledge base about dietary supplement use in cancer and consider all of the data when advising patients. Strategies that are patient-centered and reflect the complete array of available evidence lead to more nuanced messages about dietary supplement use in cancer. This should encourage greater disclosure of use by patients and ultimately increase safety and efficacy for patients choosing to use dietary supplements during cancer care.
    Hematology/Oncology Clinics of North America 08/2008; 22(4):581-617, vii. DOI:10.1016/j.hoc.2008.04.012 · 2.30 Impact Factor
  • American Journal of Ophthalmology 10/2000; 130(4):543-543. DOI:10.1016/S0002-9394(00)00746-7 · 3.87 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Epidemiological studies show a link between the consumption of plant-derived foods and a range of health benefits. These benefits have been associated, at least partially, to some of the phytochemical constituents, and, in particular, to polyphenols. In the last few years, nutraceuticals have appeared in the market. These are pharmaceutical forms (pills, powders, capsules, vials, etc.) containing food bioactive compounds as active principles. The bioactive phytochemicals have become a very significant source for nutraceutical ingredients. Scientific research supports the biological activity of many of these food phytochemicals, but the health claims attributed to the final marketed nutraceutical products have often little or doubtful scientific foundation. This is due to the fact that a lot of the scientific evidence is derived from animal testing and in vitro assays, whereas human clinical trials are scarce and inconclusive. Some key issues such as bioavailability, metabolism, dose/response and toxicity of these food bioactive compounds or the nutraceuticals themselves have not been well established yet. Amongst the phytochemicals, several groups of polyphenols (anthocyanins, proanthocyanidins, flavanones, isoflavones, resveratrol and ellagic acid) are currently used in the nutraceutical industry. In this report, we have reviewed the most recent scientific knowledge on the bioavailability and biological activity of these polyphenols ('fact'), as well as the health claims (which are not always supported by scientific studies) ascribed to the polyphenols-containing nutraceuticals ('fiction'). The in vitro antioxidant capacity, often used as a claim, can be irrelevant in terms of in vivo antioxidant effects. Bioavailability, metabolism, and tissue distribution of these polyphenols in humans are key factors that need to be clearly established in association to the biological effects of these polyphenols-containing nutraceuticals. The future trends of phytochemistry research regarding nutraceuticals are discussed.
    Phytochemistry 11/2007; 68(22-24):2986-3008. DOI:10.1016/j.phytochem.2007.09.014 · 2.55 Impact Factor
Show more